A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
31 July, 2025
World Lung Cancer Day: Focus on the TROG Lung Working Party
TROG WORKING PARTY IN FOCUS: 31 July 2025 To
29 July, 2025
TROG 21.07 SOCRATES HCC Trial Expands Outreach
TRIAL IN FOCUS: 29 July 2025 We’ve extended the
